๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Intrahepatic Cholangiocarcinoma
Clinical trial register · China

Intrahepatic Cholangiocarcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 9 Guangzhou 3 Jinan 2 Hangzhou 2 Hanzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai9 Guangzhou3 Jinan2 Hangzhou2 Hanzhou2
All 16 locations
Target enrolment
to

Intrahepatic Cholangiocarcinoma trials in China

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
NCT07522476Intrahepatic Cholangiocarcinoma
DrugVG2025
Virogin Biotech Ltd.
Phase 2
30
Hangzhou
2026-07-01
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
NCT07641036Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
NCT07570849Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2026-03-01
Recruiting
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4ฮฑ srRNA in Treating Advanced ICC Patients
NCT06583993Intrahepatic Cholangiocarcinoma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
9
Shanghai
2024-11-07
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
NCT06643208Intrahepatic Cholangiocarcinoma
Fujian Provincial Hospital
Observational
37
Fuzhou
2024-07-01
Recruiting
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
NCT06406816Intrahepatic Cholangiocarcinoma
Yongyi Zeng
Phase EARLY_PHASE1
10
Fuzhou
2024-05-06
Recruiting
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
NCT06298968Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2
38
Guangzhou
2024-04-26
Recruiting
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
NCT06296563Intrahepatic Cholangiocarcinoma
Lei ZHAO
Phase 2
20
Jinan
2024-03-01
Recruiting
Neoadjuvant Therapy of HAIC๏ผˆGEMOX๏ผ‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT06208462Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05342194Intrahepatic Cholangiocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
480
Shanghai
2023-06-19
Recruiting
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
NCT05557578Intrahepatic Cholangiocarcinoma
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou, Hanzhou
2023-05-05
Active, closed
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
NCT06239532Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2
28
Jinan
2022-09-27
Recruiting
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
NCT05010681Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
25
Shanghai
2021-08-24
Recruiting
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT04954781Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
25
Shanghai
2021-07-14
Active, closed
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT04669496Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
Shanghai Zhongshan Hospital
Phase 2/3
178
Shanghai
2021-01-20
Active, closed
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
NCT04295317Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2
65
Shanghai
2020-08-01
Recruiting
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
NCT04299581Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
25
Shanghai
2020-07-07
Recruiting
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
NCT04078230Intrahepatic Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
168
Beijing, Guangzhou, Changsha, Hohhot, Shanghai, Xiโ€™an, Chengdu, Hanzhou
2020-01-01
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/intrahepatic-cholangiocarcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Intrahepatic Cholangiocarcinoma.

How many Intrahepatic Cholangiocarcinoma trials are recruiting in China?

15 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Intrahepatic Cholangiocarcinoma), 20 studies
PhaseStudiesRecruitingShare
Phase 213965%
Phase EARLY_PHASE12210%
Not applicable115%
Observational115%
Phase 1/2115%
Phase 2/3105%
Phase 3115%

Most active sponsors

Lead sponsors with the most studies (Intrahepatic Cholangiocarcinoma)
Lead sponsorStudiesRecruiting
Fudan University33
Shanghai Zhongshan Hospital31
Anhui Provincial Hospital11
Beijing Biotech11
Fujian Provincial Hospital11
Lei ZHAO11
Nanfang Hospital, Southern Medical University11
Qilu Hospital of Shandong University10
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Shanghai Changzheng Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.